张颖杰
个人信息Personal Information
副教授 博士生导师 硕士生导师
性别:男
毕业院校:山东大学
学历:研究生(博士)毕业
学位:医学博士学位
在职信息:在职
所在单位:药学院
入职时间:2013-02-28
电子邮箱:zhangyingjie@sdu.edu.cn
扫描关注
- 暂无内容
- . Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer. Journal of Medicianal Chemistry, 66, 2024.
- . Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. J. Med. Chem. , 66, 10080, 2023.
- Anil Kumar Marapaka. Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization. CHINESE CHEMICAL LETTERS, 2550, 2022.
- 薛霞. Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. Investigational New Drugs , 40, 10-20, 2022.
- 许启富. Inhibitors of the GTPase KRAS(G12C) in cancer: a patent review (2019-2021). Expert Opinion on Therapeutic Patents, 32, 475, 2022.
- 李顺达. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. Bioorganic Chemistry, 105278, 2022.
- 具有抗肝细胞癌耐药、复发和转移优势的组蛋白去乙酰化酶11亚型选择性抑制剂的发现和研究, 2022/09/07-2026/12/31
- EZH2抑制剂Tazemetostat的合成工艺研究, 2022/03/21-2025/12/31
- 抗恶性肿瘤转移、侵袭的新型MMP/HDAC双靶点抑制剂的研究, 2019/12/19-2021/12/31
- 新型HDAC/JAK双靶点抗肿瘤药物研发, 2019/04/12-2022/12/31
- 多靶点型乌苯美司前药衍生物设计咨询, 2014/09/20-2017/09/20
- 基于肿瘤干细胞标志物APN/CD13为靶标的抗癌先导物的发现, 2013/08/15-2017/12/31
- 暂无内容